Ecron Acunova, the clinical research organization major, has entered into a global strategic alliance with Essential CRO to strengthen its service offerings in emerging markets. This alliance provides pharmaceutical, biotechnology, device, diagnostic and nutritional sponsors with access to 18 countries in key emerging sectors for clinical research.

The alliance network is established through a combination of Essential CRO's presence in Gurnee, Illinois with Ecron Acunova, based in Bangalore, India with its US office in Princeton, New Jersey and an established presence, headquartered in Frankfurt, Germany, across 14 countries in Europe.

According to Lee Jones president & CEO of Essential CRO that this alliance provides immediate global capability to its sponsors through an experienced best-in-class operations. The combined size of 350 employees will ensure that the alliance maintains the ability to meet unique sponsor needs in a timely manner.

Driving advantages of Europe and India, D A Prasanna, founder of Ecron Acunova said that the alliance adds over 20 years of clinical trial experience of conducting trials for marketing authorizations in the key markets of US and EU and the fast patient recruitment advantage of Central and East Europe and India.

Essential's therapeutic database of over 4,500 studies makes its feasibility unique, and its global patient recruitment expertise has unmatched results. Further, sponsors see benefit in speedy completion of early development studies with Ecron Acunova's PK/PD, central lab and biometric services under one roof. While both partners offer full-service CRO operations independently, their execution synergy is enhanced when operating together, rivalling the capability of any competing CRO, he added.

Essential and Ecron Acunova have been partners for several years, but the magnitude of project size and positive sponsor feedback on the combined team execution have been instrumental in establishing this alliance. The alliance has passed several international clients QA audits over the past two years reinforcing the quality of execution. In the past six months the alliance has won key global projects in the eight figure range in over 14 countries from leading mid-sized biotech and large pharma sponsors reflecting a winning edge and profitable alliance.